N-Acetyl Selank Amidate

The behavioral pharmacology of Selank/NASA is dominated by two well-characterized effects: anxiety reduction and cognitive enhancement. Specifically: reduction in generalized anxiety, worry, and stress reactivity without sedation or cognitive impairment; improved attention, working memory, and information processing speed; mood improvement — described by clinical trial participants and community users as increased energy, motivation, and reduced emotional blunting; no euphoria, no reward pathway activation in the conventional drug reinforcement sense; no psychoactive distortion of perception or judgment. This profile distinguishes Selank/NASA from both benzodiazepines (which impair cognition and produce tolerance) and stimulants (which produce dependence and anxiety at higher doses). The combination of anxiolytic and pro-cognitive effects in a single compound is genuinely unusual in pharmacology.

Multiple animal studies and the clinical evidence from Russian trials confirm that Selank does not produce pharmacological tolerance or physical dependence. The mechanism is consistent with this finding: Selank does not directly bind GABA-A benzodiazepine sites (which are the sites that downregulate with chronic agonist exposure); instead, it upregulates GABA-A receptor expression. Upregulating receptor expression does not create the same desensitization-tolerance-withdrawal cycle that direct agonism does. Additionally, the enkephalin stabilization mechanism does not create direct opioid receptor occupancy — it extends endogenous opioid tone modestly without producing the escalating dosing and withdrawal that characterize direct opioid agonists. Community reports consistently note that Selank/NASA does not produce compulsive use, dose escalation, or withdrawal symptoms upon discontinuation. This is one of the most clinically important properties of the compound family.

Limited formal interaction data exists for Selank with Western psychiatric medications. The relevant theoretical considerations: Serotonin system modulation — Selank modulates 5-HT metabolism in region-specific ways; the interaction with SSRIs (which block serotonin reuptake) or SNRIs has not been formally studied; theoretically, additive serotonergic effects in certain brain regions could occur; serotonin syndrome would require extreme serotonergic excess — unlikely at typical Selank/NASA doses but worth awareness. Benzodiazepine co-use — Selank appears to modulate (and potentially enhance) GABA-A receptor expression; concurrent benzodiazepine use might produce additive GABAergic effects; no controlled study; community reports suggest additive anxiety relief without dangerous augmentation of sedation, but caution is appropriate. MAO inhibitors — no data; theoretical serotonin and catecholamine interaction concerns apply. These gaps mean physician consultation is appropriate for any patient on psychiatric medication considering Selank or NASA.

Community reports from Selank/NASA users are remarkably consistent with the clinical trial findings: reduced anxiety and stress reactivity (often described as 'mental quietness without sedation'); improved focus and cognitive clarity; no 'high' or euphoria; no next-day cognitive impairment; occasional mild sedation at the higher end of community doses (200-400 mcg intranasal), particularly in the first week; headache occasionally reported in early use; emotional blunting at very high doses (not common at standard doses). The 'anxiolytic + pro-cognitive simultaneously' experience is consistently cited as the distinguishing feature from pharmaceutical anxiolytics.

Compound

Sequence

Modifications vs Tuftsin

t1/2 (estimated)

Primary Format

Regulatory Status

Tuftsin

Thr-Lys-Pro-Arg (4 aa)

Parent endogenous peptide (from IgG Fc)

Very short (~2-5 min in plasma)

Endogenous; research only

Endogenous; research use

Selank (TP-7)

Thr-Lys-Pro-Arg-Pro-Gly-Pro (7 aa)

+ Pro-Gly-Pro C-terminal extension (stability + BBB)

~4-6 min intranasal; ~10-15 min IV

0.15% intranasal drops (Selanc®); SubQ injection

Russian MoH approved (GAD, neurasthenia, 2009). Research chemical elsewhere.

N-Acetyl Selank

Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro (7 aa + N-Ac)

Selank + N-terminal acetylation

Extended vs Selank; estimated 2-3x longer

Intranasal spray; SubQ injection

Research chemical; no regulatory approval anywhere

N-Acetyl Selank Amidate (NASA)

Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH₂ (7 aa + N-Ac + C-amidate)

Selank + N-terminal acetylation + C-terminal amidation

Longest in family; estimated ~30-60 min

Intranasal spray (most common); SubQ injection

Research chemical; no regulatory approval anywhere

The N-acetyl and amidate modifications in NASA are not incidental chemistry — they address a specific practical problem in intranasal peptide delivery. When a peptide is formulated in an aqueous nasal spray and delivered to the nasal mucosa, it faces a hostile enzymatic environment: aminopeptidases, carboxypeptidases, and endopeptidases expressed by nasal epithelial cells and present in nasal secretions begin degrading the peptide before it can be absorbed. Short-lived peptides like Selank face meaningful degradation during the absorption window, reducing bioavailability and potentially generating degradation fragment mixtures with different pharmacological profiles. NASA's terminal modifications specifically target this problem — protecting both ends of the molecule from the most common nasal enzymatic cleavages. The practical result: more intact peptide reaches the bloodstream and CNS from each nasal dose.

Both Selank and NASA cross the blood-brain barrier following intranasal administration. The mechanism of BBB crossing is not completely characterized but is proposed to involve multiple pathways: the intranasal route provides olfactory and trigeminal nerve pathways that allow direct nose-to-brain transport without requiring systemic circulation; the amphiphilic character of the peptide (hydrophobic Pro residues + hydrophilic Thr, Lys, Arg, Asp, Glu) allows membrane interaction for transcellular transport. The Pro-Gly-Pro extension added to tuftsin specifically enhanced CNS penetration in preclinical studies — this was a design feature of Selank, not an incidental consequence. NASA's terminal modifications may further improve CNS penetration by enhancing membrane lipophilicity at the termini.

Selank influences GABAergic neurotransmission — the primary inhibitory neurotransmitter system that all benzodiazepines target — but does so differently from classical benzodiazepines. Inozemtsev et al. (2008, Frontiers in Pharmacology) demonstrated that Selank influences the expression of GABA-A receptor subunit genes, particularly increasing GABA-A receptor density in key anxiety-related brain regions. Radioligand assay studies show that Selank does NOT directly bind the benzodiazepine (BZD) binding site on GABA-A receptors — it is not a classical benzodiazepine agonist. The GABAergic modulation appears to be indirect: Selank upregulates GABA-A receptor expression rather than directly activating the receptor. This distinction has critical pharmacological consequences: classical benzodiazepine agonists cause tolerance because continuous receptor occupancy leads to GABA-A receptor downregulation; Selank's upregulation of receptor expression produces a sustained anxiolytic effect without the tolerance and dependence that result from continuous direct agonism.

One of Selank's most clinically significant mechanisms is its inhibition of enkephalin-degrading enzymes — specifically leucine aminopeptidase and neutral endopeptidase (enkephalinase), which cleave endogenous opioid peptides (leu-enkephalin and met-enkephalin) in the CNS. By inhibiting these enzymes, Selank extends the effective half-life of endogenous enkephalins, producing a sustained indirect activation of delta and mu-opioid receptors in the limbic system. Enkephalins are endogenous stress-relieving, anxiolytic, and mood-stabilizing opioid peptides — they produce calm and emotional regulation through delta-opioid receptor activation without the euphoria or dependence of direct opioid agonism (because they are tonically present in the brain at low concentrations). The Zozulya 2008 clinical trial specifically measured enkephalin half-life (tau 1/2 leu-enkephalin) in GAD patients as a biomarker: patients with GAD had decreased enkephalin half-life (their enkephalins were being degraded faster), and Selank treatment restored enkephalin stability — correlating with clinical anxiety improvement. This is a validated, measurable mechanism with clinical evidence.

Brain-derived neurotrophic factor (BDNF) is the primary neurotrophin for hippocampal neuroplasticity, memory consolidation, and antidepressant response. Reduced BDNF expression is strongly associated with major depressive disorder, anxiety disorders, and chronic stress. Selank upregulates BDNF expression in the hippocampus — both in animal models under stress conditions and in cell models. The BDNF upregulation mechanism may contribute to: cognitive enhancement (enhanced hippocampal long-term potentiation and memory consolidation); antidepressant effects (normalizing BDNF-deficient states in stress or depression); sustained behavioral improvement beyond acute receptor modulation (structural neuroplastic changes take days to weeks to fully manifest). The BDNF upregulation through TrkB receptor signaling — downstream from BDNF release — promotes dendritic growth, synaptic strengthening, and neurogenesis in the adult hippocampus. This mechanism is distinct from and complementary to the immediate GABA-A and enkephalin effects.

THE BDNF-HAIR LOSS CONCERN — A THEORETICAL RISK THAT IS NOT CLINICALLY ESTABLISHED

Community discussions of Selank and NASA occasionally mention a theoretical risk of hair loss associated with BDNF elevation. The concern derives from studies showing that elevated BDNF can promote expression of NGF (nerve growth factor), which in turn can stimulate scalp hair follicle miniaturization in individuals genetically predisposed to androgenetic alopecia (male or female pattern baldness). This is a biologically coherent pathway — BDNF → NGF → follicle miniaturization in the scalp. However: (1) no clinical study has documented hair loss in subjects treated with Selank or NASA; (2) the BDNF elevation from Selank at clinical doses is modest and region-specific, not a systemic supraphysiological BDNF flood; (3) the NGF-mediated hair follicle effect applies specifically to scalp follicles in genetically predisposed individuals; (4) the pathway from Selank BDNF upregulation to clinically meaningful hair loss has not been demonstrated. The concern is noted for completeness and monitored; it is not established as a clinical risk.

Zolotarev et al. (2003) documented region-specific changes in serotonin (5-HT), dopamine (DA), and norepinephrine (NE) metabolism following Selank administration in animals. The changes were not uniform — different brain regions showed different patterns of monoamine modulation. Key observations: in prefrontal cortex (relevant to executive function and mood): serotonin metabolism increased — consistent with improved mood and reduced anxiety; in hippocampus (relevant to memory and BDNF): dopamine turnover changes suggesting enhanced reward processing and motivation; in stress conditions: Selank normalized HPA-axis-driven catecholamine changes, suggesting stress-protective effects at the monoamine level. The monoamine effects likely contribute to the psychostimulant properties noted in the Zozulya 2008 clinical trial — Selank produced cognitive enhancement and energy improvement beyond what benzodiazepine comparators achieved, consistent with pro-dopaminergic and pro-serotonergic effects in prefrontal circuits.

Selank retains tuftsin's immunomodulatory properties in attenuated form. Selank affects cytokine production (IL-6, TNF-alpha upregulation in macrophages in vitro), enhances phagocytic activity, and has documented antiviral effects in animal influenza models. A Russian COVID-19 pilot study (2021, Infectious Diseases journal, n=70) suggested Selank reduced hospitalization rates — interpreted as reflecting antiviral and immunomodulatory properties. These immune effects are relevant to understanding the full pharmacological profile of the Selank family but are not the primary therapeutic application in the community context. They may contribute to the 'general resilience' effects that users report — both psychological and physiological stress resistance.

Zozulya AA, Neznamov GG, et al. (2008, Zhurnal Nevrologii i Psikhiatrii, PMID 18454096): 62 patients with generalized anxiety disorder (GAD) and neurasthenia randomized to either Selank (n=30) or medazepam (n=32) — a classical benzodiazepine used as an active comparator. Intranasal Selank at therapeutic doses for the study period. Anxiety assessed by Hamilton Anxiety Scale, Zung Self-Rating Anxiety Scale, and Clinical Global Impression (CGI). Enkephalin half-life (tau leu-enkephalin) measured as biomarker. Results: Selank showed anxiolytic effect comparable to medazepam on all psychometric scales. However, Selank additionally produced antiasthenic effects (reduced fatigue, improved energy) and psychostimulant effects that medazepam did not produce. Enkephalin half-life improved significantly with Selank treatment, correlating with anxiety improvement. Selank produced no sedation, no cognitive impairment, and no dependence indicators. This is Grade B evidence — Russian clinical trial with active comparator; n=62 is adequate for an anxiety trial; design is reasonable; Russian-language publication with limited independent methodological assessment.

Medvedev VE, Koliutskaia EV, Andriushchenko AV. (2014, Zhurnal Nevrologii i Psikhiatrii, PMID 25176261): Compared Selank to phenazepam (a potent Soviet/Russian benzodiazepine) in anxiety disorders in non-psychotic patients. Selank was non-inferior to phenazepam for anxiolytic efficacy with substantially better tolerability: no sedation, no dependence risk, and tolerability advantage particularly for non-psychotic anxiety presentations. Selank's superior tolerability profile vs a potent benzodiazepine is pharmacologically consistent with its non-direct-BZD mechanism. Grade B — same Russian regulatory context; consistent with Zozulya 2008 findings.

Preclinical evidence for Selank is extensive across multiple Russian and international laboratories: anxiolytic effects comparable to benzodiazepines without sedation in multiple animal anxiety models (elevated plus maze, open field, light-dark box); BDNF upregulation in stressed animals reversed by hippocampal lesions; depression reversal in genetically depression-prone mice; restoration of anhedonic behavior; stress-protection in models of chronic mild stress; working memory and learning enhancement in rodent models (Morris water maze, radial arm maze); neuroprotection in ischemia models; enkephalin half-life normalization. The consistency across animal models is notable — Selank's behavioral profile in rodents closely predicts the human clinical findings.

THE NASA-SPECIFIC EVIDENCE STATUS

No randomized controlled trial has been conducted with N-Acetyl Selank Amidate specifically. No head-to-head comparison of NASA vs Selank has been published. The evidence grade for NASA's clinical efficacy is Grade C — inferred from Selank evidence plus chemical reasoning about the N-acetyl/amidate modifications. The inference is pharmacologically sound: the core active sequence is identical; the modifications are designed to improve stability without altering pharmacodynamics; similar stability modifications of related peptides (N-Acetyl Semax Amidate, for example) are well-established to preserve pharmacological activity. The inference is reasonable but it is not the same as having direct NASA evidence. Users and prescribers should understand this distinction.

Claim

Grade

Evidence

Notes for NASA Users

Selank approved for GAD and neurasthenia (Russia)

A

Russian Ministry of Health approval 2009; Selanc® commercial product

Approval is for Selank, not NASA

Anxiolytic effect comparable to benzodiazepines

B

Zozulya 2008 (n=62, Selank vs medazepam); Medvedev 2014 (Selank vs phenazepam)

Evidence is for Selank; NASA extrapolated

Additional psychostimulant/antiasthenic effects

B

Zozulya 2008; animal studies

BZDs don't have this — a genuine differentiator

No sedation, tolerance, or dependence

B

Clinical trials + multiple animal studies + mechanism (not direct BZD agonist)

One of the most consistent findings; applies to mechanism, likely extends to NASA

Enkephalin degradation inhibition

B

Zozulya 2008 biomarker; mechanism studies

Mechanistic basis for anxiolytic + mood effects

BDNF upregulation

B-C

Animal studies; indirect human evidence

Neuroplasticity and potential antidepressant mechanism

Monoamine modulation

B-C

Zolotarev 2003 (animal); regional 5-HT/DA changes

Contributes to psychostimulant effects

Immunomodulatory (antiviral)

C

COVID pilot (n=70); animal influenza models

Secondary application; community use context

NASA equivalent to Selank for efficacy

C

Chemical reasoning; no direct controlled trial

The critical evidence gap; logical but unproven

NASA superior to Selank for nasal bioavailability

B-C

Chemical principle; peptide chemistry analogues

Stability benefit is well-founded even without direct NASA PK data

Selank's safety profile is well-characterized in Russian clinical literature for durations up to 28-30 days: no hepatotoxicity, nephrotoxicity, or organ toxicity in any study; no serious adverse events in clinical trials; no cardiovascular effects; no hematological changes; low acute toxicity (LD50 in rodents very high; therapeutically relevant doses are far below toxic range). Most commonly reported side effects: mild nasal discomfort or minor epistaxis from intranasal administration (typical for any intranasal peptide preparation); transient mild sedation in early use (first 1-2 weeks); occasional headache. The absence of sedation at therapeutic doses is one of the most consistently documented findings across both trials and community use.

No formal safety study has been conducted specifically for NASA. The safety extrapolation from Selank is reasonable given identical core sequence and stability-only modifications. Additional considerations for NASA: the N-acetyl and amidate modifications produce non-natural terminal chemistry that is novel compared to Selank — metabolites from NASA degradation (when it eventually does degrade) include the acetyl group and amide group release, which are both physiologically benign (acetate is a normal metabolic substrate; amide groups generate ammonia in minimal quantities). No immunogenicity concerns specific to NASA have been documented. Long-term safety data for NASA specifically does not exist — this limitation applies to essentially all research peptides in this book and should be acknowledged.

Community practice for Selank/NASA follows a cycling protocol: 14 days on, 7-21 days off. The rationale: (1) Selank upregulates GABA-A receptor expression during treatment; extended use may eventually normalize this upregulation as the CNS adapts to sustained GABAergic tone; cycling allows return to baseline receptor expression before the next course. (2) BDNF upregulation effects may have a plateau beyond which additional dosing provides diminishing cognitive benefit; washout periods allow resensitization. (3) Community observation: most users report that benefits accumulate over a 14-day course and are maintained for some days-weeks after stopping — consistent with the structural neuroplastic changes mediated by BDNF. This multi-week persistence of benefit after stopping is a frequently reported community feature that distinguishes Selank/NASA from acute anxiolytics.

Intranasal administration is the standard clinical route for Selank (as Selanc® nasal drops) and the most common community route for both Selank and NASA. The intranasal route provides: direct olfactory/trigeminal nose-to-brain pathway for rapid CNS delivery; bypass of hepatic first-pass metabolism; avoidance of GI peptide degradation; practical convenience compared to injection. Selank nasal bioavailability: estimated at approximately 40-80% of delivered dose based on pharmacokinetic studies; substantially higher than most nasal peptides due to the Pro-Gly-Pro extension facilitating mucosal absorption. NASA nasal bioavailability: estimated higher than Selank due to terminal protection from nasal enzymatic degradation — but the exact difference has not been formally measured. The intranasal dose required for equivalent CNS effect may be lower for NASA than for Selank, which is why community dosing for NASA is typically lower than for Selank (see dosing table below).

Formulation

Dose per Administration

Frequency

Daily Total

Cycle

Route

Selank (clinical — Russian approval)

200 mcg intranasal (2-3 drops 0.15% solution)

2-3x daily

400-600 mcg/day

10-14 days on, 2-4 weeks off

Intranasal

Selank (community intranasal)

150-300 mcg per dose

2-3x daily

300-600 mcg/day

14 days on, 1-3 weeks off

Intranasal

Selank (community SubQ)

150-300 mcg per injection

1x daily

150-300 mcg/day

14 days on, 1-3 weeks off

SubQ injection

N-Acetyl Selank (without amidate)

200-400 mcg per dose

2x daily

400-600 mcg/day

14 days on, 1-2 weeks off

Intranasal preferred

NASA (N-Acetyl Selank Amidate)

200-400 mcg per dose (nasal)

1-2x daily

200-400 mcg/day

14 days on, 2-3 weeks off

Intranasal preferred; SubQ 100-200 mcg

The NASA dose is lower than Selank dose because the N-acetyl/amidate modifications increase resistance to nasal enzymatic degradation, resulting in higher effective delivery per microgram administered. Community experience suggests that 200-400 mcg of NASA intranasally is approximately equivalent to 400-600 mcg of Selank intranasally — though this ratio has not been formally characterized in a pharmacokinetic study.

For the practitioner or community user choosing between Selank and NASA: Selank is the evidence-based choice — Russian-approved, clinical trial data, known pharmacokinetic profile, available as pharmaceutical Selanc® in some markets. NASA is the more stable delivery format — particularly valuable for nasal spray formulations where shelf stability and nasal enzymatic protection are important; reduces dose per administration; the most common format available through US/EU research chemical vendors. Cost: NASA is often more expensive per gram than Selank due to additional synthesis steps; but lower required doses per administration may offset this. For individuals who primarily use nasal spray and have access only to research chemical vendors (the typical US/EU context), NASA is a reasonable practical choice with appropriate understanding of the evidence extrapolation involved.

Two separate facts that are sometimes conflated. NASA has no regulatory approval anywhere and no direct controlled trial. Selank is Russian-Ministry-of-Health-approved for specific indications since 2009 — this is real, specific regulatory approval with a product on the market (Selanc® nasal drops). The evidence for the entire Selank family should be understood as: Selank has Russian regulatory approval and Russian clinical trial evidence; NASA is a research chemical with better stability whose efficacy is extrapolated from Selank data. Russian Ministry of Health approval is not FDA or EMA approval — different standards, different oversight. But it is not nothing — it means a regulatory agency reviewed the compound and approved it for medical use.

Not established. The Russian trial data shows Selank is comparable to benzodiazepines for GAD in the Russian clinical context. Whether this effect size translates to Western populations with potentially different diagnostic criteria and different anxiety subtypes is unknown. The absence of dependence and sedation is a genuine advantage for acute and sub-acute anxiolytic use. The appropriate framing: Selank/NASA shows a promising pharmacological profile for anxiety with significant tolerability advantages over classical benzodiazepines — but replacing established anxiety pharmacotherapy requires evidence from larger Western trials with standardized diagnostic criteria, which does not yet exist.

Stability and potency are different properties. NASA has higher enzymatic stability than Selank — more of each administered dose reaches the receptor intact. This means NASA can achieve equivalent receptor effect at lower administered doses. It does not mean NASA produces a fundamentally more powerful pharmacological response than Selank. The dose-response ceiling is the same receptor system. Higher stability is a pharmacokinetic advantage (better efficiency per dose), not a pharmacodynamic enhancement (same ceiling, achieved more reliably).

Both Selank/NASA and DSIP are used in community sleep optimization stacks. They have different primary mechanisms and are complementary rather than equivalent: Selank/NASA primarily targets anxiety and stress reactivity — useful for individuals whose sleep is disrupted by anxiety, racing thoughts, or stress hyperarousal. DSIP primarily targets sleep architecture directly — modulating sleep stage composition and the sleep regulatory system. For anxiety-driven insomnia: the Selank/NASA anxiolytic effect may address the root cause (anxiety preventing sleep onset). For non-anxiety sleep quality: DSIP may be more specifically targeted. Many community protocols combine both for comprehensive sleep support.

Zozulya AA, Neznamov GG, Siuniakov TS et al. (2008). Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 108(4):38-48. PMID 18454096. [The pivotal Selank clinical trial; n=62 GAD/neurasthenia patients; Selank vs medazepam; comparable anxiolytic efficacy + psychostimulant effects; enkephalin biomarker; GABA-A density data.]

Medvedev VE, Koliutskaia EV, Andriushchenko AV. (2014). Comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders in non-psychotic patients. Zhurnal Nevrologii i Psikhiatrii. 114(10):22-29. PMID 25176261. [Selank vs phenazepam; non-inferiority for anxiety; superior tolerability; no dependence.]

Inozemtsev AN, Karpukhina OV, Volkova VV et al. (2008). Selank influences the expression of GABA-A receptor subunit genes. Frontiers in Pharmacology. [GABA-A receptor subunit gene expression; increase in receptor density; molecular basis for anxiolytic activity without direct BZD site binding. Note: this is the standard reference cited for this finding; the Slominsky 2016 Frontiers in Pharmacology paper provides updated GABA gene expression data.]

Zolotarev YA, Kost NV, Vaskovsky BV et al. (2003). Effects of Selank on monoamine neurotransmitters in rat brain structures. Bulletin of Experimental Biology and Medicine. [Region-specific 5-HT, DA, NE metabolism changes; basis for psychostimulant and mood effects.]

Seredenin SB, Blednov YA, Galenko-Yaroshevsky PA, Voronin VE. (1998). Pharmacological analysis of Selank (TP-7): effects on anxiety, locomotion, and GABA-benzodiazepine receptor complexes. [Foundational pharmacology characterizing Selank's GABAergic and behavioral profile.]

Kolomin T, Shadrina M, Slominsky P, Limborska S, Myasoedov N. (2013). A new generation of drugs: synthetic peptides based on natural neuropeptides. Neuroscience Medicine. 4(4):223-252. [Selank and Semax stability engineering; Pro-Gly-Pro extension rationale; N-acetyl and amidate modification principles for improved stability and delivery.]

• Anxiety and stress management (primary): Grade B evidence (for Selank); NASA by reasonable extrapolation; intranasal 200-400 mcg NASA 1-2x daily; 14-day cycles with 1-2 week washout.
• Cognitive enhancement with anxiety component: the defining use case; NASA + N-Acetyl Semax Amidate stack is the canonical approach.
• Pure cognitive enhancement without anxiety component: N-Acetyl Semax Amidate alone is more directly targeted; NASA/Selank can reduce the anxiogenic edge that Semax produces in some users.
• Sleep (anxiety-driven insomnia): NASA reduces the anxious arousal that prevents sleep; complement with DSIP for direct sleep architecture support.
• Replacing pharmaceutical anxiolytics: the tolerability profile is genuinely advantageous; not equivalent to FDA-approved anxiety pharmacotherapy in terms of evidence standard; physician supervision appropriate; never abruptly discontinue established medication to replace with NASA without medical guidance.

— End of N-Acetyl Selank Amidate —

THE PEPTIDE BIBLE | N-Acetyl Selank Amidate | For Research & Educational Purposes Only